Arcturus Therapeutics Holdings Inc. (ARCT) News
Follow Arcturus Therapeutics Holdings Inc. (ARCT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 27 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Arctic Minerals Says High-Grade Metals At Hennes Bay
Arctic Minerals AB (publ) OMXSTO:ARCT
NEWS | Sep 29, 2026, 06:14 AM UTC
L
Weekly Recap: Phase2 ARCT-2601 addition and FDA pediatric ammonia endpoint
Arcturus Therapeutics Holdings, Inc. (NASDAQ:ARCT) will add ARCT-2601 to its Phase 2 ARCT-810 trial after an FDA meeting, planning year—end dosing in OTCD patients to assess safety, PK and biomarkers while pursuing longe
REGULATION | Sep 28, 2026, 11:08 AM UTC
L
Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data — But BTIG Says Therapy’s Benefit Is Hard To Measure
Arcturus Therapeutics (ARCT) was in focus Thursday after promising Phase 2 data for its experimental treatment for a rare liver disease drew broadly positive takes from analysts.ARCT shares were up nearly 7% at the time
EQUITY | Sep 24, 2026, 05:59 PM UTC
L
Arcturus Therapeutics Raised to Buy From Neutral by Citigroup
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 03:56 PM UTC
L
Arcturus Therapeutics Price Target Cut to $20.00/Share From $23.00 by BTIG
Ratings actions from Benzinga: GMT) Arcturus Therapeutics Is Maintained at Buy by BTIGRatings actions from Benzinga
NEWS | Sep 24, 2026, 09:49 AM UTC
H
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
Shares of GlucoTrack Inc (NASDAQ: GCTK ) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership. Innovate GBM, a non
LIVE | Sep 24, 2026, 09:05 AM UTC
L
Arcturus Therapeutics Announces Encouraging Interim Phase 2 Results From Arct-810 In Otc Deficiency
Arcturus Therapeutics Holdings Inc NASDAQ:ARCT
NEWS | Sep 23, 2026, 09:07 PM UTC
L
Arcturus Agrees to Buy myNEO, Reports Interim Liver Disorder Data
By Elias SchisgallArcturus Therapeutics Holdings agreed to acquire the artificial-intelligence drug discovery company myNEO and reported interim data from a phase 2 trial of a treatment for a metabolic liver disorder.Arc
MNA | Sep 23, 2026, 08:29 PM UTC
L
Arcturus Therapeutics interim ARCT-810 Phase 2 shows biomarker improvements; unveils LUNAR 2.0, plans ARCT-2601 integration
Arcturus Therapeutics reported interim Phase 2 ARCT-810 data showing improved ammonia and glutamine biomarkers and unveiled LUNAR 2.0 with >30-fold higher protein expression.Key Highlights:Original SEC Filing: Arcturus T
REGULATION | Sep 23, 2026, 08:15 PM UTC
L
Arcturus Therapeutics: Transaction Is Expected to Close in Oct >ARCT
Arcturus Therapeutics: Transaction Is Expected to Close in Oct >ARCT
NEWS | Sep 23, 2026, 08:07 PM UTC
L
Arcturus Therapeutics: To Acquire myNEO, an AI Discovery Co, to Improve mRNA Design Quality, Accelerate Innovation, Enhance Target Identification Capability >ARCT
Arcturus Therapeutics: To Acquire myNEO, an AI Discovery Co, to Improve mRNA Design Quality, Accelerate Innovation, Enhance Target Identification Capability >ARCT
MNA | Sep 23, 2026, 08:07 PM UTC
L
Arcturus Therapeutics: LUNAR 2.0 Produces Greater Than 30-Fold Higher Protein Expression in Multiple NHP Studies, Unlocks New Therapeutic Opportunities >ARCT
Arcturus Therapeutics: LUNAR 2.0 Produces Greater Than 30-Fold Higher Protein Expression in Multiple NHP Studies, Unlocks New Therapeutic Opportunities >ARCT
NEWS | Sep 23, 2026, 08:06 PM UTC
L
Arcturus Therapeutics: ARCT-810 Generally Safe and Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers in Ongoing Phase 2 Study >ARCT
Arcturus Therapeutics: ARCT-810 Generally Safe and Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers in Ongoing Phase 2 Study >ARCT
NEWS | Sep 23, 2026, 08:06 PM UTC
L
Arcturus Therapeutics Holdings Inc. (ARCT) Posts Interim OTCD Phase 2 Data; Unveils LUNAR 2.0
Arcturus reported interim Phase 2 data for ARCT-810 in OTC deficiency and introduced LUNAR 2.0, which showed up to ~40-fold potency gains in NHPs. It plans to integrate ARCT-2601 into the ongoing Phase 2 near year-end, a
MNA | Sep 23, 2026, 08:01 PM UTC
L
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase
NEWS | Sep 23, 2026, 08:01 PM UTC
L
ARCT: Upcoming phase II data and a pivotal CF decision mark major milestones for the mRNA pipeline
The session highlighted differentiated mRNA technologies, a robust rare disease pipeline, and regained global control of a leading COVID vaccine. Key near-term milestones include a phase II data readout for OTC deficienc
NEWS | Sep 15, 2026, 05:22 PM UTC
L
ARCT: Near-term clinical milestones and regained vaccine control drive strong commercial prospects
The session highlighted differentiated mRNA technologies, a robust rare disease pipeline, and near-term milestones including a phase II data readout for OTC deficiency and a pivotal CF program decision in Q4. Strategic p
NEWS | Sep 15, 2026, 04:27 PM UTC
L
ARCT: Advanced copper projects in the Nordics progress amid regulatory support and key drilling milestones
The presentation highlighted a strong focus on copper and critical metals, with advanced projects in Sweden and Norway and a robust five-year development plan. Regulatory improvements and community engagement are support
COMMODITIES | Sep 15, 2026, 07:33 AM UTC
L
ARCT: Advanced copper projects and regulatory support drive growth, with key drilling results imminent
The presentation highlighted a strong focus on copper and critical metals, with advanced projects in Sweden and Norway, regulatory support, and robust community engagement. Key milestones include imminent drilling result
COMMODITIES | Sep 15, 2026, 07:08 AM UTC
L
ARCT OTC deficiency and CF programs near regulatory and phase milestones
ARCT says upcoming phase II data and regulatory updates for its OTC deficiency program will clarify pediatric and adult path forward. CF program runs a 12-week open-label study; phase III decision and major funding tied
EQUITY | Sep 09, 2026, 02:49 PM UTC
M
ARCT to seek Q4 go/no-go for CF inhaled mRNA Phase III
ARCT said Q4 will bring a go/no-go decision on advancing its cystic fibrosis inhaled mRNA therapy to Phase III, alongside imminent Phase II data and OTC deficiency program regulatory updates. The plan cites a $40M Thermo
EQUITY | Sep 09, 2026, 02:28 PM UTC
L
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Aug 31, 2026, 08:01 PM UTC
L
Arcturus Therapeutics shares are trading higher after the company announced a strategic collaboration with Thermo Fisher Scientific to help
Arcturus Therapeutics shares are trading higher after the company announced a strategic collaboration with Thermo Fisher Scientific to help support the Phase 3 development and potential commercialization of ARCT-032. Als
EQUITY | Jul 02, 2026, 03:39 PM UTC
H
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) is collaborating with Thermo Fisher Scientific Inc. (NYSE: TMO ) to support the Phase 3 development and potential commercialization of ARCT-032, the company’s investiga
MACRO | Jul 02, 2026, 03:32 PM UTC
L
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Jef
EQUITY | Jul 02, 2026, 11:21 AM UTC
L
Arcturus Therapeutics Collaborates With Thermo Fisher Scientific To Help Support Phase 3 Development And Potential Commercialization Of ARCT
Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights Arcturus Therapeutics Holdings Inc. (("Arcturus", NASDAQ: ARCT ), a messenger RNA medicines company focused on the de
EQUITY | Jul 02, 2026, 11:02 AM UTC
L
Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $27
Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ: ARCT ) with a Buy rating and announces Price Target of $27.
EQUITY | Jul 02, 2026, 09:47 AM UTC